Key result
DES outperforms DEB for DES restenosis, while prolonged DAPT is linked to higher stroke risk.
Why the study?
Data regarding the duration of dual antiplatelet therapy in patients with drug-eluting stent restenosis treated with PCI using drug-eluting balloons or DES were not unambiguous.
Does prolonged dual antiplatelet therapy (>6 months) improve long-term outcomes in patients undergoing PCI for drug-eluting stent restenosis with drug-eluting balloons or stents?
Observational (n=1,367)
Yes
Does prolonged dual antiplatelet therapy (>6 months) improve long-term outcomes in patients undergoing PCI for drug-eluting stent restenosis with drug-eluting balloons or stents?
In patients with DES-ISR, DAPT duration > 6 months is associated with a higher risk of stroke without clear ischemic benefit, while PCI with DES yields better long-term outcomes than DEB.
Answers are grounded in this paper and cite their sources.
DES superior to DEB for DES-ISR long-term; >6-month DAPT associated with higher stroke risk, leaving optimal duration open for RCTs.
Introduction: Data regarding the duration of dual antiplatelet therapy (DAPT) in patients with drug-eluting stent restenosis (DES-ISR) treated with percutaneous coronary intervention (PCI) and drug-eluting balloons (DEB) or DES are not unambiguous. Aim: To evaluate the relationship between long-term outcomes and the length of DAPT in patients treated with PCI due to DES-ISR with DEB or DES. Material and methods: Overall, a total of 1,367 consecutive patients with DES-ISR, who underwent PCI with DEB or DES between 2008 and 2019 entered the study. The mean length of the follow-up was 1,298.7 ±794 days. We assessed study endpoints according to the duration of DAPT (≤ 3 vs. > 3 and ≤ 6 vs. > 6 months) before and after propensity score matching (PSM): stroke, target lesion revascularisation (TLR), target vessel revascularisation (TVR), myocardial infarction (MI), death and device oriented composite endpoints (DOCE). Kaplan-Meier estimates were created to differentiate long-term outcomes. Conclusions: Treatment with DAPT in patients with DES-ISR is related to better long-term outcomes in the case of PCI with DES than DEB. DAPT > 6 months is related to the greater rate of strokes, independently of the type of treatment (DES and DEB) than DAPT ≤ 6 months.
No takes yet. Share an insight, caveat, or question.
Januszek et al. (2022) conducted an observational in Drug-eluting stent restenosis (DES-ISR) (n=1,367). Dual antiplatelet therapy (DAPT) > 3 months or > 6 months vs. DAPT ≤ 3 months or ≤ 6 months was evaluated on Target lesion revascularisation (TLR) for DEB with DAPT > 3 vs. ≤ 3 months (HR 1.97, 95% CI 1.06-3.65, p=0.03). In patients with drug-eluting stent restenosis, treatment with drug-eluting stents resulted in better long-term outcomes than drug-eluting balloons, and dual antiplatelet therapy for more than 6 months was associated with a higher stroke rate compared to 6 months or less.
Synapse has enriched 10 related papers. Consider them for comparative context: